• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
CommentaryRoe v. Wade

With Roe v. Wade out, we need male contraception more than ever

By
Akash Bakshi
Akash Bakshi
Down Arrow Button Icon
By
Akash Bakshi
Akash Bakshi
Down Arrow Button Icon
July 29, 2022, 6:15 AM ET
Hormonal contraceptive methods for women come with side effects such as mood changes, depression, an increased risk of breast and cervical cancer, and blood clots. But when it comes to men, it is widely assumed side effects would be unacceptable.
Hormonal contraceptive methods for women come with side effects such as mood changes, depression, an increased risk of breast and cervical cancer, and blood clots. But when it comes to men, it is widely assumed side effects would be unacceptable.Getty Images

Roe v. Wade has been overturned, resulting in reduced access to safe and effective abortions. It’s a devastating moment for the health and well-being of American women and individuals who can become pregnant.

We should consider why women need abortions in the first place. For many (but not all–some women require abortions for medical reasons), it’s unintended pregnancy. For every two pregnant women in America, one of their pregnancies is unintended. About 40% of those women choose to have an abortion, which is now outlawed in as many as 28 states in America. 

But unplanned isn’t a synonym for unprotected. As many as 50% of couples observed in a study by the Guttmacher Institute were actively using a contraceptive when they became pregnant. It won’t be a surprise to learn that condoms are behind many well-intentioned yet failed efforts to prevent pregnancy. The pill, too, can fail: 12% of women who seek an abortion were on the pill. 

Of course, the protections previously granted by Roe must be codified into law. But we also need better contraceptives. We always have. We need to empower people to prevent unwanted pregnancy and the need for abortion. We can also increase access to highly effective contraceptives and bring men into the conversation. After all, women don’t get pregnant alone.  

Efficacy aside, nearly every woman who is on a hormonal contraceptive weighs side effects that include mood changes, depression, an increased risk of breast and cervical cancer, and blood clots.

Male birth control doesn’t exist today beyond the technologies developed in the 1800s: condoms, which come with high failure rates, or vasectomies, which aren’t yet reliably reversible. But if it did, we could decrease unintended pregnancies and, in today’s America, unsafe abortions. 

We need men to claim their full equal responsibility for reproductive health–and it’s not an unrealistic notion. Nearly 75% of women and about 72% of men believe both sexual partners should be equally responsible for birth control. There is a massive untapped market for novel male contraceptives that are highly effective, reversible, and convenient to use. There is also a glaring gap in interest, research, and funding in the field of male reproduction. Biologically, it’s challenging: successful contraception requires us to stop millions of sperm from reaching an egg, and it’s difficult to target human sperm cells.

To suggest that men aren’t looking beyond the condom simply doesn’t reflect the current mood: A recent survey showed that 17 million American men are seeking better contraceptive methods for themselves. 

This wasn’t always the case, of course: It’s widely believed that demand for male contraceptive methods didn’t exist until after paternity tests were developed, putting men on the hook for raising their own offspring.

Regardless, it’s a whole new era for heterosexual women and their relationship with male partners. The #MeToo movement and the 2017 Women’s March on Washington come to mind as flashpoints for modern feminism which aim to hold the country’s most powerful men to account and include a focus on sexual empowerment centered on women’s pleasure. 

Still, many assumed men would be turned off by the possibility of side effects, which suggests a gross double standard in which side effects are acceptable for women but unacceptable for men–a notion that also does not align with the values that younger generations are striving for. 

Let’s empower men to step up during a moment when women’s access to safe and effective abortions is now in grave danger. 

An affordable, reversible contraceptive for men is possible. Private companies are commercializing therapeutics and devices that non-hormonally bring sperm counts below fertile limits in men, essentially offering the benefits of a highly effective contraceptive to men. Other institutions are trialing hormonal methods with tentatively promising efficacy. 

These developments give me hope that someday we can decrease the hormonal burden we put on women in the name of preventing pregnancy. It’s a burden that has compelled so many women to share their stories with me about the effects of birth control on their lives. It’s personal and real. The development of male contraceptives covered by insurance and widely adopted by men can radically change that.

Attacks on reproductive autonomy and a lack of male birth control have put women in devastating positions. But if we’re to decrease the need for abortion, we’ll need men to take on a fair share of responsibility in preventing unwanted pregnancies–and a whole lot of research, funding, and awareness to get us there.

Akash Bakshi is the CEO and co-founder of YourChoice Therapeutics, a company that is developing a birth control pill for men. Akash holds degrees in Biochemistry and Cell Biology from UC San Diego and University of Queensland.

The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not reflect the opinions and beliefs of Fortune.

More must-read commentary published by Fortune:

  • COVID got me. Will it come for you?
  • Why remote work will win this fall
  • A list of companies supporting abortion rights after the Roe v. Wade ruling shows which firms are stepping up, and why
  • Career hoarding is on the rise—but it comes at a cost
  • Venture capital is hard–and it’s supposed to be

Sign up for the Fortune Features email list so you don’t miss our biggest features, exclusive interviews, and investigations.

About the Author
By Akash Bakshi
See full bioRight Arrow Button Icon

Latest in Commentary

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Commentary

mallun
AISoftware
Your enterprise customers don’t know how to buy AI — and it’s killing deals
By Mallun YenMarch 27, 2026
19 hours ago
krueger
CommentarySafety
Rogue AI is already here
By David KruegerMarch 27, 2026
21 hours ago
kennnedy
CommentaryDrugs
America is handing its mRNA lead to China—and RFK Jr. is to blame
By Jeff CollerMarch 26, 2026
2 days ago
jerry
CommentaryEducation
The college degree isn’t dead. But the wrong kind could cost you $2 million
By Jerry BalentineMarch 26, 2026
2 days ago
trump
CommentaryMarkets
We’re no longer in a bull or bear market. We’re in a Trump market — and here’s how to navigate it
By Jeffrey Sonnenfeld and Steven TianMarch 26, 2026
2 days ago
EuropeLetter from London
Rishi Sunak is giving advice to CEOs on AI. Here are his golden rules
By Kamal AhmedMarch 25, 2026
3 days ago

Most Popular

Success
Meetings are not work, says Southwest Airlines CEO—and he’s taking action by blocking his calendar every afternoon from Wednesday to Friday 
By Fortune EditorsMarch 27, 2026
23 hours ago
AI
Exclusive: Anthropic acknowledges testing new AI model representing ‘step change’ in capabilities, after accidental data leak reveals its existence
By Fortune EditorsMarch 26, 2026
1 day ago
Personal Finance
Current price of gold as of March 27, 2026
By Fortune EditorsMarch 27, 2026
19 hours ago
AI
Exclusive: Anthropic left details of an unreleased model, invite-only CEO retreat, sitting in an unsecured data trove in a significant security lapse
By Fortune EditorsMarch 26, 2026
1 day ago
Personal Finance
Current price of silver as of Friday, March 27, 2026
By Fortune EditorsMarch 27, 2026
19 hours ago
Commentary
The Treasury just declared the U.S. insolvent. The media missed it
By Fortune EditorsMarch 23, 2026
5 days ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.